EVFM — Evofem Biosciences, Inc.

OTC · Health Care · Pharmaceuticals · CIK 1618835 ·
Last close
$0.01
Market Cap
$874.7K
52W High
$0.01
52W Low
$0.00
ADV30
288,725
Next earnings
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 899,000 489,000 -4,569,000 -5,465,000 7,442,000 1,491,000 85,072,000
Dec 2025 9,561,000 6,969,000 3,345,000 2,788,000 20,274,000 94,610,000
Sep 2025 4,952,000 4,047,000 -982,000 -1,569,000 13,807,000 0 88,873,000
Jun 2025 4,825,000 4,070,000 -1,251,000 -1,784,000 14,382,000 0 83,998,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,992,000
Investing CF
$-62,000
Financing CF
$1,891,000
CapEx
$-3,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.06
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-897,390,000
Inventory
$1,129,000
Receivables
$12,857,000
ST Investments
$202,000
EBIT TTM
$1,439,000
Pretax Income TTM
$393,000
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$20,237,000
EBITDA
$-3,089,000
Free Cash Flow
$-1,038,125
Enterprise Value
$56,735,724
Total Cash
$1,620,000
Total Debt
$52,457,000
Shares Out
132,530,081
Trailing EPS
$-0.05
Book Value
$-0.59
ROE
ROA
-21.3%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 20,183,000 1,439,000 391,000 20,274,000 94,610,000 -1,992,000
Dec 2024 19,363,000 -7,676,000 -8,860,000 23,789,000 95,046,000 -3,885,000
Dec 2023 18,218,000 -17,847,000 52,979,000 10,554,000 77,064,000 -8,968,000
Dec 2022 16,837,000 -84,124,000 -76,698,000 25,163,000 96,963,000 -70,410,000

TTM Snapshot

Revenues TTM
$2,025,000
NetIncome TTM
$-136,189,000
OpCashFlow TTM
$0
Assets (Latest)
$42,512,000
Forward EPS
$-0.55

Peers — same industry

TickerNameMarket CapLastDaily %
PTIX Protagenic Therapeutics, Inc.\new $842.5K $0.47
SKVI SKINVISIBLE, INC. $924.6K $0.17
ATXI AVENUE THERAPEUTICS, INC. $757.8K $0.23
OWPC One World Products, Inc. $720.7K $0.01
EMMA Emmaus Life Sciences, Inc. $701.9K $0.01

News headlines (Yahoo Finance, 1h cache)

Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-18 12:55 · Yahoo
Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa
2026-04-27 13:25 · Yahoo
Evofem Reports Fifth Consecutive Year of Net Sales Growth
2026-03-11 20:05 · Yahoo
Evofem CEO Saundra Pelletier Calls for a "Ground-Up Reset" of Women’s Health at Fierce JPM Week 2026
2026-01-23 14:25 · Yahoo
Evofem Expands "Say Vagina" Campaign With Launch of Say Vagina Store
2026-01-21 16:00 · Yahoo
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
2025-11-21 14:25 · Yahoo
Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update
2025-11-13 21:05 · Yahoo
Evofem Announces Voting Results from Special Meeting of Stockholders
2025-10-20 20:18 · Yahoo
Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates
2025-10-01 12:47 · Yahoo
Evofem Biosciences Honors World Contraception Day
2025-09-26 12:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.